Ganciclovir for Cytomegalovirus after Heart Transplantation
To the Editor: Although the study by Merigan et al. (April 30 issue) 1 demonstrated that the use of ganciclovir as prophylaxis for cytomegalovirus (CMV) infection in heart-transplant recipients was associated with fewer cases of CMV disease than was placebo, the clinical importance of this benefit i...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 1992-09, Vol.327 (12), p.891-893 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 893 |
|---|---|
| container_issue | 12 |
| container_start_page | 891 |
| container_title | The New England journal of medicine |
| container_volume | 327 |
| creator | Bailey, Thomas C Trulock, Elbert P Storch, Gregory A Powderly, William G Winston, Drew J Laske, Andreas Gallino, Augusto Carrel, Thierry Turina, Marko I Merigan, Thomas C Renlund, Dale Buhles, William Stinson, Edward |
| description | To the Editor:
Although the study by Merigan et al. (April 30 issue)
1
demonstrated that the use of ganciclovir as prophylaxis for cytomegalovirus (CMV) infection in heart-transplant recipients was associated with fewer cases of CMV disease than was placebo, the clinical importance of this benefit is unclear. The definition of CMV syndrome, for example, may have included cases of very mild illness. Furthermore, the patients at highest risk for serious disease (i.e., CMV-seronegative recipients of organs from CMV-seropositive donors) received no benefit from the described course of prophylaxis. We found no benefit from an early, brief course of ganciclovir in . . . |
| doi_str_mv | 10.1056/NEJM199209173271215 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73147320</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73134939</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-cf88b7ca26c9694586e7faf888810d5d1b5abeb56cc65b8a3ed374b85bf9d3343</originalsourceid><addsrcrecordid>eNqNkM9LwzAUx4Moc07_AhF68iLVpC9pEzxJmZsy9TLPIUlT6WjambTC_nurHXgR8V0evO8PHh-Ezgm-JpilN8_zxyciRIIFySDJSELYAZoSBhBTitNDNMU44THNBByjkxA2eBhCxQRNCCSUApmi24VqTGXq9qPyUdn6KN91rbNv6vvSh0iVnfXR0irfRWuvmrCtVdOprmqbU3RUqjrYs_2eodf7-TpfxquXxUN-t4oNCNHFpuRcZ0YlqRGpoIynNivVcOSc4IIVRDOlrWapMSnTXIEtIKOaM12KAoDCDF2OvVvfvvc2dNJVwdh6eMS2fZAZEDoAwP8xAhUgBiOMRuPbELwt5dZXTvmdJFh-sZW_sB1SF_v6Xjtb_GRGmIN-NerOBdnYjfuz7RNiJ4Cw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73134939</pqid></control><display><type>article</type><title>Ganciclovir for Cytomegalovirus after Heart Transplantation</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Bailey, Thomas C ; Trulock, Elbert P ; Storch, Gregory A ; Powderly, William G ; Winston, Drew J ; Laske, Andreas ; Gallino, Augusto ; Carrel, Thierry ; Turina, Marko I ; Merigan, Thomas C ; Renlund, Dale ; Buhles, William ; Stinson, Edward</creator><creatorcontrib>Bailey, Thomas C ; Trulock, Elbert P ; Storch, Gregory A ; Powderly, William G ; Winston, Drew J ; Laske, Andreas ; Gallino, Augusto ; Carrel, Thierry ; Turina, Marko I ; Merigan, Thomas C ; Renlund, Dale ; Buhles, William ; Stinson, Edward</creatorcontrib><description>To the Editor:
Although the study by Merigan et al. (April 30 issue)
1
demonstrated that the use of ganciclovir as prophylaxis for cytomegalovirus (CMV) infection in heart-transplant recipients was associated with fewer cases of CMV disease than was placebo, the clinical importance of this benefit is unclear. The definition of CMV syndrome, for example, may have included cases of very mild illness. Furthermore, the patients at highest risk for serious disease (i.e., CMV-seronegative recipients of organs from CMV-seropositive donors) received no benefit from the described course of prophylaxis. We found no benefit from an early, brief course of ganciclovir in . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199209173271215</identifier><identifier>PMID: 1324431</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Cytomegalovirus Infections - prevention & control ; Ganciclovir - therapeutic use ; Humans ; Organ Transplantation ; Postoperative Complications - prevention & control</subject><ispartof>The New England journal of medicine, 1992-09, Vol.327 (12), p.891-893</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-cf88b7ca26c9694586e7faf888810d5d1b5abeb56cc65b8a3ed374b85bf9d3343</citedby><cites>FETCH-LOGICAL-c399t-cf88b7ca26c9694586e7faf888810d5d1b5abeb56cc65b8a3ed374b85bf9d3343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199209173271215$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJM199209173271215$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1324431$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bailey, Thomas C</creatorcontrib><creatorcontrib>Trulock, Elbert P</creatorcontrib><creatorcontrib>Storch, Gregory A</creatorcontrib><creatorcontrib>Powderly, William G</creatorcontrib><creatorcontrib>Winston, Drew J</creatorcontrib><creatorcontrib>Laske, Andreas</creatorcontrib><creatorcontrib>Gallino, Augusto</creatorcontrib><creatorcontrib>Carrel, Thierry</creatorcontrib><creatorcontrib>Turina, Marko I</creatorcontrib><creatorcontrib>Merigan, Thomas C</creatorcontrib><creatorcontrib>Renlund, Dale</creatorcontrib><creatorcontrib>Buhles, William</creatorcontrib><creatorcontrib>Stinson, Edward</creatorcontrib><title>Ganciclovir for Cytomegalovirus after Heart Transplantation</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
Although the study by Merigan et al. (April 30 issue)
1
demonstrated that the use of ganciclovir as prophylaxis for cytomegalovirus (CMV) infection in heart-transplant recipients was associated with fewer cases of CMV disease than was placebo, the clinical importance of this benefit is unclear. The definition of CMV syndrome, for example, may have included cases of very mild illness. Furthermore, the patients at highest risk for serious disease (i.e., CMV-seronegative recipients of organs from CMV-seropositive donors) received no benefit from the described course of prophylaxis. We found no benefit from an early, brief course of ganciclovir in . . .</description><subject>Cytomegalovirus Infections - prevention & control</subject><subject>Ganciclovir - therapeutic use</subject><subject>Humans</subject><subject>Organ Transplantation</subject><subject>Postoperative Complications - prevention & control</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkM9LwzAUx4Moc07_AhF68iLVpC9pEzxJmZsy9TLPIUlT6WjambTC_nurHXgR8V0evO8PHh-Ezgm-JpilN8_zxyciRIIFySDJSELYAZoSBhBTitNDNMU44THNBByjkxA2eBhCxQRNCCSUApmi24VqTGXq9qPyUdn6KN91rbNv6vvSh0iVnfXR0irfRWuvmrCtVdOprmqbU3RUqjrYs_2eodf7-TpfxquXxUN-t4oNCNHFpuRcZ0YlqRGpoIynNivVcOSc4IIVRDOlrWapMSnTXIEtIKOaM12KAoDCDF2OvVvfvvc2dNJVwdh6eMS2fZAZEDoAwP8xAhUgBiOMRuPbELwt5dZXTvmdJFh-sZW_sB1SF_v6Xjtb_GRGmIN-NerOBdnYjfuz7RNiJ4Cw</recordid><startdate>19920917</startdate><enddate>19920917</enddate><creator>Bailey, Thomas C</creator><creator>Trulock, Elbert P</creator><creator>Storch, Gregory A</creator><creator>Powderly, William G</creator><creator>Winston, Drew J</creator><creator>Laske, Andreas</creator><creator>Gallino, Augusto</creator><creator>Carrel, Thierry</creator><creator>Turina, Marko I</creator><creator>Merigan, Thomas C</creator><creator>Renlund, Dale</creator><creator>Buhles, William</creator><creator>Stinson, Edward</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19920917</creationdate><title>Ganciclovir for Cytomegalovirus after Heart Transplantation</title><author>Bailey, Thomas C ; Trulock, Elbert P ; Storch, Gregory A ; Powderly, William G ; Winston, Drew J ; Laske, Andreas ; Gallino, Augusto ; Carrel, Thierry ; Turina, Marko I ; Merigan, Thomas C ; Renlund, Dale ; Buhles, William ; Stinson, Edward</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-cf88b7ca26c9694586e7faf888810d5d1b5abeb56cc65b8a3ed374b85bf9d3343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Cytomegalovirus Infections - prevention & control</topic><topic>Ganciclovir - therapeutic use</topic><topic>Humans</topic><topic>Organ Transplantation</topic><topic>Postoperative Complications - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bailey, Thomas C</creatorcontrib><creatorcontrib>Trulock, Elbert P</creatorcontrib><creatorcontrib>Storch, Gregory A</creatorcontrib><creatorcontrib>Powderly, William G</creatorcontrib><creatorcontrib>Winston, Drew J</creatorcontrib><creatorcontrib>Laske, Andreas</creatorcontrib><creatorcontrib>Gallino, Augusto</creatorcontrib><creatorcontrib>Carrel, Thierry</creatorcontrib><creatorcontrib>Turina, Marko I</creatorcontrib><creatorcontrib>Merigan, Thomas C</creatorcontrib><creatorcontrib>Renlund, Dale</creatorcontrib><creatorcontrib>Buhles, William</creatorcontrib><creatorcontrib>Stinson, Edward</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bailey, Thomas C</au><au>Trulock, Elbert P</au><au>Storch, Gregory A</au><au>Powderly, William G</au><au>Winston, Drew J</au><au>Laske, Andreas</au><au>Gallino, Augusto</au><au>Carrel, Thierry</au><au>Turina, Marko I</au><au>Merigan, Thomas C</au><au>Renlund, Dale</au><au>Buhles, William</au><au>Stinson, Edward</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ganciclovir for Cytomegalovirus after Heart Transplantation</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>1992-09-17</date><risdate>1992</risdate><volume>327</volume><issue>12</issue><spage>891</spage><epage>893</epage><pages>891-893</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
Although the study by Merigan et al. (April 30 issue)
1
demonstrated that the use of ganciclovir as prophylaxis for cytomegalovirus (CMV) infection in heart-transplant recipients was associated with fewer cases of CMV disease than was placebo, the clinical importance of this benefit is unclear. The definition of CMV syndrome, for example, may have included cases of very mild illness. Furthermore, the patients at highest risk for serious disease (i.e., CMV-seronegative recipients of organs from CMV-seropositive donors) received no benefit from the described course of prophylaxis. We found no benefit from an early, brief course of ganciclovir in . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>1324431</pmid><doi>10.1056/NEJM199209173271215</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 1992-09, Vol.327 (12), p.891-893 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73147320 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Cytomegalovirus Infections - prevention & control Ganciclovir - therapeutic use Humans Organ Transplantation Postoperative Complications - prevention & control |
| title | Ganciclovir for Cytomegalovirus after Heart Transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T02%3A06%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ganciclovir%20for%20Cytomegalovirus%20after%20Heart%20Transplantation&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Bailey,%20Thomas%20C&rft.date=1992-09-17&rft.volume=327&rft.issue=12&rft.spage=891&rft.epage=893&rft.pages=891-893&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJM199209173271215&rft_dat=%3Cproquest_cross%3E73134939%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73134939&rft_id=info:pmid/1324431&rfr_iscdi=true |